HAART and CD4+ T cells protect positive people from toxoplasmic encephalitis
10 January 2002. Related: Coinfections and complications.
2002
KS-associated herpesvirus epidemic in San Francisco gay men predates HIV epidemic; oral sex is a likely risk for infection
10 January 2002. Related: Coinfections and complications.
HAART has little effect on anal cancer precursor lesions or on HPV
10 January 2002. Related: Cancer and HIV.
HAART improves anaemia in HIV-positive patients
10 January 2002. Related: Coinfections and complications.
Unexplained vision loss in AIDS patients calls for fluorescein angiography
10 January 2002. Related: Coinfections and complications.
Doubt over use of antioxidant vitamins for the prevention of coronary disease
10 January 2002. Related: Side effects.
Endocrine disorders complicate ARV treatment
10 January 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Birth defects linked to use of certain drugs during pregnancy
10 January 2002. Related: Paediatric care.
Immune reconstitution in children treated with HAART is independent of age and pre-treatment immune status
10 January 2002. Related: Paediatric care.
Protease inhibitor based HAART and lymphoid regeneration
10 January 2002. Related: Basic science and immunology.
New findings explain T-cell loss in HIV infection
9 January 2002. Related: Basic science and immunology.
Voluntary suspension of Kava-kava sales following safety concerns
9 January 2002. Related: Other news.
The Chapman Clinic: musculoskeletal treatment for patients with HIV
9 January 2002. Related: Other news.
41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001
9 January 2002. Related: Conference reports.
Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients
9 January 2002. Related: Conference reports, Hepatitis coinfection.
Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir
9 January 2002. Related: Conference reports, Drug resistance.
Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
9 January 2002. Related: Conference reports, Antiretrovirals.
Immune reconstitution more difficult with low baseline CD4+ T cell counts
9 January 2002. Related: Conference reports.
HIV-1 may revert to less pathogenic strain a few days after starting HAART
9 January 2002. Related: Conference reports, Basic science and immunology.
Change from CCR5 to CXCR4 phenotype may affect immunologic responses
9 January 2002. Related: Conference reports.
ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
9 January 2002. Related: Conference reports, Antiretrovirals.
Swatch study: should we be cycling drugs?
9 January 2002. Related: Conference reports, Antiretrovirals.
New HIV drugs, resistance, pharmacogenomics
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy
9 January 2002. Related: Conference reports, Antiretrovirals.
Immunopathogenesis of HIV infection
9 January 2002. Related: Conference reports.
Additional reports from ICAAC 2001
9 January 2002. Related: On the web.
Double scourge: tuberculosis and HIV coinfection
9 January 2002. Related: On the web.
The road to eradication: is HAART hard enough?
9 January 2002. Related: On the web.